|
1
|
Cazacu SM, Iordache S, Iovănescu VF,
Streba L, Neagoe CD, Busuioc CJ, Cârţu D and Florescu MM: The role
of CDX2, MUC5AC, and p53 in the evaluation of the progression of
serrated lesions toward colorectal carcinoma. Rom J Morphol
Embryol. 66:99–109. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023.PubMed/NCBI
|
|
3
|
Tong G, Wang Y, Qian H, Tan Z, Shen Y and
Li H: The effects of two combined methods of P53 expression and
preoperative serum CEA detection on the prognosis of colorectal
cancer. Front Oncol. 15:15908362025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tong GJ, Zhang GY, Liu J, Zheng ZZ, Chen
Y, Niu PP and Xu XT: Comparison of the eighth version of the
American Joint Committee on Cancer manual to the seventh version
for colorectal cancer: A retrospective review of our data. World J
Clin Oncol. 9:148–161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tong G, Shen Y, Li H, Qian H and Tan Z:
NLRC4, inflammation and colorectal cancer (Review). Int J Oncol.
65:992024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tong G, Xu W, Zhang G, Liu J, Zheng Z,
Chen Y, Niu P and Xu X: The role of tissue and serum
carcinoembryonic antigen in stages I to III of colorectal cancer-A
retrospective cohort study. Cancer Med. 7:5327–5338. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tong G, Zhang G, Hu Y, Xu X and Wang Y:
Correlation between mismatch repair statuses and the prognosis of
stage I–IV colorectal cancer. Front Oncol. 13:12783982024.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tong G, Li H, Shen Y, Tan Z and Qian H:
The combined evaluation of preoperative serum CEA and postoperative
tissue CEA as a prognostic factor in stages 0-IV colorectal cancer:
A retrospective cohort study. Front Med (Lausanne). 11:14470412025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sirniö P, Elomaa H, Tuomisto A, Äijälä VK,
Karjalainen H, Kastinen M, Tapiainen VV, Sirkiä O, Ahtiainen M,
Helminen O, et al: CDX2 and SATB2 loss are associated with myeloid
cell infiltration and poor survival in colorectal cancer. Cancer
Immunol Immunother. 74:1112025. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beck F: The role of Cdx genes in the
mammalian gut. Gut. 2004.53:1394–1396. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sweetser S, Smyrk TC and Sinicrope FA:
Serrated colon polyps as precursors to colorectal cancer. Clin
Gastroenterol Hepatol. 11:760–767; quiz e54-5. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balbinot C, Armant O, Elarouci N, Marisa
L, Martin E, De Clara E, Onea A, Deschamps J, Beck F, Freund JN and
Duluc I: The Cdx2 homeobox gene suppresses intestinal tumorigenesis
through non-cell-autonomous mechanisms. J Exp Med. 215:911–926.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu J, Liu D, Sun X, Yang K, Yao J, Cheng
C, Wang C and Zheng J: CDX2 inhibits the proliferation and tumor
formation of colon cancer cells by suppressing Wnt/β-catenin
signaling via transactivation of GSK-3β and Axin2 expression. Cell
Death Dis. 10:262019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jahan S, Awaja N, Hess B, Hajjar S, Sad S
and Lohnes D: The transcription factor Cdx2 regulates inflammasome
activity through expression of the NLRP3 suppressor TRIM31 to
maintain intestinal homeostasis. J Biol Chem. 298:1023862022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang YS, Kou Y, Zhu RT, Han BW, Li CH,
Wang HJ, Wu HB, Xia TM and Che XM: CDX2 as a predictive biomarker
involved in immunotherapy response suppresses metastasis through
EMT in colorectal cancer. Dis Markers. 2022:90256682022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu Y, Hryniuk A, Foley T, Hess B and
Lohnes D: Cdx2 Regulates Intestinal EphrinB1 through the Notch
Pathway. Genes (Basel). 12:1882021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mehmood MS and Danaf N: Bacteroides
fragilis toxin in colorectal tumors activates STAT3 and drives
microsatellite instability. Ann Med Surg (Lond). 88:957–958. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arnold A, Tronser M, Sers C, Ahadova A,
Endris V, Mamlouk S, Horst D, Möbs M, Bischoff P, Kloor M and
Bläker H: The majority of β-catenin mutations in colorectal cancer
is homozygous. BMC Cancer. 20:10382020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leskela S, Romero I, Cristobal E,
Pérez-Mies B, Rosa-Rosa JM, Gutierrez-Pecharroman A, Santón A,
Gonzalez BO, López-Reig R, Hardisson D, et al: The frequency and
prognostic significance of the histologic type in early-stage
ovarian carcinoma: A reclassification study by the spanish group
for ovarian cancer research (GEICO). Am J Surg Pathol. 44:149–161.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan WY, Chua W, Wilkinson K, Epitakaduwa
C, Mandaliya H, Descallar J, Roberts TL, Becker TM, Ng W, Lee CS
and Lim SH: The Prognostic and Predictive Utility of CDX2 in
Colorectal Cancer. Int J Mol Sci. 25:86732024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kamal R, Paul P and Diksha Awasthi A:
Exploring gene therapy: The next generation of colorectal cancer
treatment. Curr Gene Ther. 25:195–198. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu Z, Yu Y, Ni H, Sun W and Kuang Y:
LINC01836 promotes colorectal cancer progression and functions as
ceRNA to Target SLC17A9 by Sponging miR-1226-3p. Protein Pept Lett.
31:43–60. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suleman M, Khan SU, Ali S, Alghamdi A,
Alissa M, Mushtaq RY and Crovella S: Probing the Depths of
Molecular Complexity: STAT3 as a Key Architect in Colorectal Cancer
Pathogenesis. Curr Gene Ther. 25:433–452. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Qian F, Shan B, Zhang L, Zhong J,
Chen S, Yao M, Li S, Cao X, Fei S and Pang X: TFF3 initiates
gastric intestinal metaplasia by activating JAK2 and STAT3 under
high salt conditions. Sci Rep. 15:235762025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee JA, Park HE, Jin HY, Jin L, Yoo SY,
Cho NY, Bae JM, Kim JH and Kang GH: The combination of CDX2
expression status and tumor-infiltrating lymphocyte density as a
prognostic factor in adjuvant FOLFOX-treated patients with stage
III colorectal cancers. J Pathol Transl Med. 59:50–59. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mukohyama J, Koizumi M, Yamashita K,
Yoshimi A, Shida D and Kakeji Y: Knockdown of CDX2 Induces
microRNA-221 Up-regulation in Human colon cancer cells. Anticancer
Res. 44:3553–3556. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Voutsadakis IA: CDX2-Suppressed colorectal
cancers possess potentially targetable alterations in receptor
tyrosine kinases and other colorectal-cancer-associated pathways.
Diseases. 12:2342024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bae JM, Lee TH, Cho NY, Kim TY and Kang
GH: Loss of CDX2 expression is associated with poor prognosis in
colorectal cancer patients. World J Gastroenterol. 21:1457–1467.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cecchini MJ, Walsh JC, Parfitt J,
Chakrabarti S, Correa RJ, MacKenzie MJ and Driman DK: CDX2 and Muc2
immunohistochemistry as prognostic markers in stage II colon
cancer. Hum Pathol. 90:70–79. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fuentes Bayne HE, Suleiman R, Eiring RA,
McGarrah PW, Thome SD, Graham RP, Garcia JJ and Halfdanarson TR:
CDX2 expression as a predictive and prognostic biomarker of 5-FU
response in cancer of unknown primary. ESMO Open. 10:1055152025.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Slik K, Turkki R, Carpén O, Kurki S,
Korkeila E, Sundström J and Pellinen T: CDX2 loss with
microsatellite stable phenotype predicts poor clinical outcome in
stage II colorectal carcinoma. Am J Surg Pathol. 43:1473–1482.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wouters VM, Helderman RFCPA, Cameron K,
van der Hooff SR, Torang A, van den Bergh S, Jackstadt R, Sansom
OJ, van Neerven SM and Medema JP: CDX2 downregulation regulates
intrinsic WNT pathway activation, dictating metastasis in APC and
CTNNB1 wildtype colorectal cancer. Oncogene. 44:2091–2102. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arcos M, Goodla L, Kim H, Desai SP, Liu R,
Yin K, Liu Z, Martin DR and Xue X: PINK1-deficiency facilitates
mitochondrial iron accumulation and colon tumorigenesis. Autophagy.
21:737–753. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hassan S, Mirza T, Khatoon A, Bukhari U,
Shaikh F and Karim A: BRAF mutations and the association of V600E
with CD133 and CDX2 expression in a Pakistani colorectal carcinoma
cohort. BMC Cancer. 24:11622024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dzung A, Saltari A, Tiso N, Lyck R, Dummer
R and Levesque MP: STK11 Prevents invasion through signal
transducer and activator of transcription 3/5 and FAK repression in
cutaneous melanoma. J Invest Dermatol. 142:1171–1182.e10. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Konukiewitz B, Schmitt M, Silva M, Pohl J,
Lang C, Steiger K, Halfter K, Engel J, Schlitter AM, Boxberg M, et
al: Loss of CDX2 in colorectal cancer is associated with
histopathologic subtypes and microsatellite instability but is
prognostically inferior to hematoxylin-eosin-based morphologic
parameters from the WHO classification. Br J Cancer. 125:1632–1646.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saad RS, Ghorab Z, Khalifa MA and Xu M:
CDX2 as a marker for intestinal differentiation: Its utility and
limitations. World J Gastrointest Surg. 3:159–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kaimaktchiev V, Terracciano L, Tornillo L,
Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M,
Sauter G and Corless CL: The homeobox intestinal differentiation
factor CDX2 is selectively expressed in gastrointestinal
adenocarcinomas. Mod Pathol. 17:1392–1399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Werling RW, Yaziji H, Bacchi CE and Gown
AM: CDX2, a highly sensitive and specific marker of adenocarcinomas
of intestinal origin: An immunohistochemical survey of 476 primary
and metastatic carcinomas. Am J Surg Pathol. 27:303–310. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Choi BJ, Kim CJ, Cho YG, Song JH, Kim SY,
Nam SW, Lee SH, Yoo NJ, Lee JY and Park WS: Altered expression of
CDX2 in colorectal cancers. APMIS. 114:50–54. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sayar I, Akbas EM, Isik A, Gokce A, Peker
K, Demirtas L and Gürbüzel M: Relationship among mismatch repair
deficiency, CDX2 loss, p53 and E-cadherin in colon carcinoma and
suitability of using a double panel of mismatch repair proteins by
immunohistochemistry. Pol J Pathol. 66:246–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Davidsen J, Jessen SB, Watt SK, Larsen S,
Dahlgaard K, Kirkegaard T, Gögenur I and Troelsen JT: CDX2
expression and perioperative patient serum affects the adhesion
properties of cultured colon cancer cells. BMC Cancer. 20:4262020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hryniuk A, Grainger S, Savory JG and
Lohnes D: Cdx1 and Cdx2 function as tumor suppressors. J Biol Chem.
289:33343–33354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Platet N, Hinkel I, Richert L,
Murdamoothoo D, Moufok-Sadoun A, Vanier M, Lavalle P, Gaiddon C,
Vautier D, Freund JN and Gross I: The tumor suppressor CDX2 opposes
pro-metastatic biomechanical modifications of colon cancer cells
through organization of the actin cytoskeleton. Cancer Lett.
386:57–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
da Silva JL, de Albuquerque LZ, Rodrigues
FR, Bastos NC, Small IA, Barroso EBC, Cordero FL, Fernandes DS,
Paulino E and de Melo AC: Exploring biomarkers and prognostic
factors in uterine carcinosarcoma: An insight into L1CAM, CDX2,
p53, and MSI status. PLoS One. 18:e02854472023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kato S, Koshino A, Lasota J, Komura M,
Wang C, Ebi M, Ogasawara N, Kojima K, Tsuzuki T, Kasai K, et al:
Use of SATB2 and CDX2 Immunohistochemistry to Characterize and
Diagnose Colorectal Cancer. Appl Immunohistochem Mol Morphol.
32:362–370. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Caldas ÁMC, Nunes WA, Taboada R, Cesca MG,
Germano JN and Riechelmann RP: Loss of CDX2 and high COX2 (PTGS2)
expression in metastatic colorectal cancer. Ecancermedicalscience.
18:16662024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yu J, Li S, Xu Z, Guo J, Li X, Wu Y, Zheng
J and Sun X: CDX2 inhibits epithelial-mesenchymal transition in
colorectal cancer by modulation of Snail expression and β-catenin
stabilisation via transactivation of PTEN expression. Br J Cancer.
124:270–280. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen K, Collins G, Wang H and Toh JWT:
Pathological features and prognostication in colorectal cancer.
Curr Oncol. 28:5356–5383. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jain R, Sansoni ER, Angel J, Gleysteen JP,
Hayes DN and Owosho AA: salivary duct carcinoma with rhabdoid
features of the parotid gland with No E-Cadherin Expression: A
Report with Anti-HER2 therapy and review of the literature. Dent J
(Basel). 11:2292023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Veraguas-Dávila D, Saéz-Ruíz D, Álvarez
MC, Saravia F, Castro FO and Rodríguez-Alvarez L: Analysis of
trophectoderm markers in domestic cat blastocysts cultured without
zona pellucida. Zygote. 30:841–848. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bahrami A, Jafari A and Ferns GA: The dual
role of microRNA-9 in gastrointestinal cancers: OncomiR or tumor
suppressor? Biomed Pharmacother. 145:1123942022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Perna C, Navarro A, Ruz-Caracuel I,
Caniego-Casas T, Cristóbal E, Leskelä S, Longo F, Caminoa A, Santón
A, Ferreiro R, et al: Molecular heterogeneity of high grade
colorectal adenocarcinoma. Cancers (Basel). 13:2332021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Melincovici CS, Boşca AB, Şuşman S, Cutaş
A, Mărginean M, Ilea A, Moldovan IM, Jianu EM, Neag MA, Bulboacă AE
and Mihu CM: Assessment of mismatch repair deficiency, CDX2,
beta-catenin and E-cadherin expression in colon cancer: Molecular
characteristics and impact on prognosis and survival-an
immunohistochemical study. Rom J Morphol Embryol. 61:715–727. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang JF, Qu LS, Qian XF, Xia BL, Mao ZB
and Chen WC: Nuclear transcription factor CDX2 inhibits gastric
cancercell growth and reverses epithelialtomesenchymal transition
in vitro and in vivo. Mol Med Rep. 12:5231–5238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ilie-Petrov AC, Cristian DA, Diaconescu
AS, Chitul A, Blajin A, Popa A, Mandi DM, Negreanu R, Vieru C,
Vrîncianu R and Ardeleanu CM: Molecular deciphering of colorectal
cancer: Exploring molecular classifications and analyzing the
interplay among molecular biomarkers MMR/MSI, KRAS, NRAS, BRAF and
CDX2-A comprehensive literature review. Chirurgia (Bucur).
119:136–155. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
da Silveira Santos JPL, Machado CJ, Junior
EP, Rodrigues J, Vidigal PT and Resende V: Immunohistochemical
predictors for intestinal and pancreatobiliary types of
adenocarcinoma of the ampulla of vater. J Gastrointest Surg.
22:1171–1178. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Puccini A, Berger MD, Zhang W and Lenz HJ:
What we know about stage II and III colon cancer: It's still not
enough. Target Oncol. 12:265–275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bruun J, Sveen A, Barros R, Eide PW,
Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A,
Kallioniemi O, et al: Prognostic, predictive, and pharmacogenomic
assessments of CDX2 refine stratification of colorectal cancer. Mol
Oncol. 12:1639–1655. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Shi X, Lu L, Wang Z, Dai Y, Hu S, Wu Z, Yu
R, Liu T, Jiang Y, Ma Y, et al: The potential role of tumor
deposits in the prognosis and TNM staging for colorectal cancer. J
Gastrointest Oncol. 15:2473–2495. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zeng J, Fan W, Li J, Wu G and Wu H:
KRAS/NRAS mutations associated with distant metastasis and
BRAF/PIK3CA mutations associated with poor tumor differentiation in
colorectal cancer. Int J Gen Med. 16:4109–4120. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Dong XF, Wang Y, Tang CH, Huang BF, Du Z,
Wang Q, Shao JK, Lu HJ and Wang CQ: Upregulated WTAP expression in
colorectal cancer correlates with tumor site and differentiation.
PLoS One. 17:e02637492022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Delhorme JB, Bersuder E, Terciolo C, Vlami
O, Chenard MP, Martin E, Rohr S, Brigand C, Duluc I, Freund JN and
Gross I: CDX2 controls genes involved in the metabolism of
5-fluorouracil and is associated with reduced efficacy of
chemotherapy in colorectal cancer. Biomed Pharmacother.
147:1126302022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Mochizuki K, Kudo SE, Kato K, Kudo K,
Ogawa Y, Kouyama Y, Takashina Y, Ichimasa K, Tobo T, Toshima T, et
al: Molecular and clinicopathological differences between depressed
and protruded T2 colorectal cancer. PLoS One. 17:e02735662022.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Badia-Ramentol J, Gimeno-Valiente F,
Duréndez E, Martínez-Ciarpaglini C, Linares J, Iglesias M,
Cervantes A, Calon A and Tarazona N: The prognostic potential of
CDX2 in colorectal cancer: Harmonizing biology and clinical
practice. Cancer Treat Rev. 121:1026432023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Aydin SG, Olmez OF, Selvi O, Geredeli C,
Ozden F, Bilici A, Acikgoz O, Karci E, Kutlu Y, Hamdard J and Aydin
A: The prognostic role of mismatch repair status and CDX-2
expression with inflammatory markers and pathological risk factors
in stage II and III colon cancer: Multicenter real-life data. J
Gastrointest Cancer. 55:227–236. 2024. View Article : Google Scholar : PubMed/NCBI
|
